Belkin Re-introduces InvisiGlass: Reliable Screen Protection, Now Made With Recycled Glass
Belkin, a leading consumer electronics brand for 40 years, today announced its reimagined InvisiGlass screen protection collection, made with certified recycled glass. The InvisiGlass screen protection collection is now available on belkin.com for iPhone 16, iPhone 16 Plus, iPhone 16 Pro, and iPhone 16 Pro Max.
Belkin InvisiGlass is made with glass materials that are collected and recycled during the manufacturing process, certified by the Global Recycled Standard (GRS), and thoroughly tested to ensure the premium quality, durability, reliability and clarity that the brand name is known for.
Fortified with ion-exchange technology, InvisiGlass screen protectors are 62%2 more durable than tempered glass screen protectors without adding thickness or weight to provide best-in-class protection while maintaining the device’s natural look and feel.
The ScreenForce™ InvisiGlass collection includes:
- InvisiGlass – $29.99 USD – the new InvisiGlass is an upgrade to the original InvisiGlass Ultra material introduced in 2017. The new version is enhanced with recycled glass while still smooth to the touch and ultra-thin, preserving touchscreen sensitivity.
- InvisiGlass Blue Light Filter – $34.99 USD – incorporates industry-leading blue light reduction technology by Eyesafe to filter out 60% of blue light3. It is designed to support eye comfort for more enjoyable screen time, whether working, reading, or streaming.
- InvisiGlass Privacy – $34.99 USD – engineered with an added privacy filter to keep emails, webpages, texts and photos protected from prying eyes. It is the ideal solution for working on sensitive documents, banking online, or simply browsing the web or social media.
Belkin InvisiGlass Screen Protectors come in 100% recycled packaging4 using paper certified by the Forest Stewardship Council. The package contains a cleaning cloth, dust removal sticker to prevent air bubbles, and patented Easy Align tray for flawless alignment and fool-proof application.
For more information on Belkin InvisiGlass, see here: www.belkin.com/screenforce/sustainability
Pricing and Availability
The Belkin InvisiGlass Screen Protector collection for the new iPhone 16 lineup is available on belkin.com today for $29.99 – $34.99 USD and coming soon to major retailers worldwide.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
_________________________
1 Glass is made with a minimum of 60% post-industrial recycled glass and has been certified through GRS.
2 Based on internal tests, screen protectors can withstand up to 62% more force on average compared to conventional tempered glass screen protectors.
3 435-440 nm
4 Recycled plastic components include Easy Align tray, support tray, top protective film, and protective bags.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909753989/en/
Contacts
Media Contact
Jen Wei
VP of Global Communications and Corporate Development
comms@belkin.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics30.12.2024 07:50:00 CET | Press Release
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/ Follow Project-Comfort LinkedIn Page: https://www.linkedin.
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 20:00:00 CET | Press Release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 12:00:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 07:00:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom